Open study of sitafloxacin in patients with respiratory tract infections - PK/PD study

Atsushi Saito, Yusuke Tanigawara, Akira Watanabe, Nobuki Aoki, Yoshihito Niki, Shigeru Kohno, Mitsuo Kaku, Seiji Hori, Kyoichi Totsuka

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Sitafloxacin(STFX), a fluoroquinolone antimicrobial agent, has a broad spectrum of activity and a potent antimicrobial activity against Streptococcus pneumoniae which is a major pathogen in respiratory tract infections(RTI). This clinical study was conducted to confirm the clinical recommended dose of STFX as 50 mg b. i.d. for RTI from PK/PD. Clinical efficacy was 92.3% (96/104) in the 50 mg b.i.d, group and 93.1% (27/29) in the 100 mg b.i.d, group. Bacteriological efficacy was 89.1% (57/64) in the 50 mg b.i.d, group and 82.4% (14/17) in the 100 mg b.i.d. group. Eradication of major causative organisms was 91.7% (22/24) in S. pneumoniae and 100% (24/24) in Haemophilus influenzae. Steady state Cmax and AUC0-24h after repeated oral administration of STFX to patients with RTI were 0.57 ± 0.21 μg/mL and 9.38 ± 424 μg · h/mL in the 50 mg b.i.d, group, and 1.17 ± 0.45 μg/mL and 17.16 ± 6.52 χ • h/mL in the 100 mg b.i.d. group. If Cmax/MIC was 5 or below, or AUC0-24h/MIC was 100 or below, eradication were 33.3% (3/9) or 40.0% (4/10). In contrast, if Cmax/MIC was over 5, it was 96.3% (79/82). If AUC0-24h/MIC was over 100, it was 96.3% (78/81). MIC90 of STFX against the causative organisms in this study was 0.1 μg/mL. Results suggest that 50 mg b.i.d of STFX can achieve Cmax/MIC5 and AUC0-24h/ MIC 100 against 90% of the causative organisms in RTI. Adverse drug reactions(ADR) occurred in 43.5% (50/115 patients) in the 50 mg b.i.d, group and 42.4% (14/33 patients) in the 100 mg b.i.d, group. The major ADR was diarrhoea (20/148, 13.5%). Cmax and AUC0-24h of patients in whom diarrhoea or soft stool occurred tended to be higher than in patients free of these symptoms. No severe ADRs were observed in either groups. Results suggest that a dose of 50 mg b.i.d, of STFX is optimal in the treatment of RTI.

Original languageEnglish
Pages (from-to)63-80
Number of pages18
JournalJapanese Journal of Chemotherapy
Volume56
Issue numberSUPPL. 1
Publication statusPublished - 2008 Apr

Fingerprint

Respiratory Tract Infections
Streptococcus pneumoniae
Drug-Related Side Effects and Adverse Reactions
Diarrhea
Fluoroquinolones
Haemophilus influenzae
Anti-Infective Agents
Oral Administration
sitafloxacin

Keywords

  • Fluoroquinolone
  • PK/PD
  • Respiratory tract infection
  • Sitafloxacin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Saito, A., Tanigawara, Y., Watanabe, A., Aoki, N., Niki, Y., Kohno, S., ... Totsuka, K. (2008). Open study of sitafloxacin in patients with respiratory tract infections - PK/PD study. Japanese Journal of Chemotherapy, 56(SUPPL. 1), 63-80.

Open study of sitafloxacin in patients with respiratory tract infections - PK/PD study. / Saito, Atsushi; Tanigawara, Yusuke; Watanabe, Akira; Aoki, Nobuki; Niki, Yoshihito; Kohno, Shigeru; Kaku, Mitsuo; Hori, Seiji; Totsuka, Kyoichi.

In: Japanese Journal of Chemotherapy, Vol. 56, No. SUPPL. 1, 04.2008, p. 63-80.

Research output: Contribution to journalArticle

Saito, A, Tanigawara, Y, Watanabe, A, Aoki, N, Niki, Y, Kohno, S, Kaku, M, Hori, S & Totsuka, K 2008, 'Open study of sitafloxacin in patients with respiratory tract infections - PK/PD study', Japanese Journal of Chemotherapy, vol. 56, no. SUPPL. 1, pp. 63-80.
Saito, Atsushi ; Tanigawara, Yusuke ; Watanabe, Akira ; Aoki, Nobuki ; Niki, Yoshihito ; Kohno, Shigeru ; Kaku, Mitsuo ; Hori, Seiji ; Totsuka, Kyoichi. / Open study of sitafloxacin in patients with respiratory tract infections - PK/PD study. In: Japanese Journal of Chemotherapy. 2008 ; Vol. 56, No. SUPPL. 1. pp. 63-80.
@article{e4aaeec44fd6425ea540dc4ee47ba09e,
title = "Open study of sitafloxacin in patients with respiratory tract infections - PK/PD study",
abstract = "Sitafloxacin(STFX), a fluoroquinolone antimicrobial agent, has a broad spectrum of activity and a potent antimicrobial activity against Streptococcus pneumoniae which is a major pathogen in respiratory tract infections(RTI). This clinical study was conducted to confirm the clinical recommended dose of STFX as 50 mg b. i.d. for RTI from PK/PD. Clinical efficacy was 92.3{\%} (96/104) in the 50 mg b.i.d, group and 93.1{\%} (27/29) in the 100 mg b.i.d, group. Bacteriological efficacy was 89.1{\%} (57/64) in the 50 mg b.i.d, group and 82.4{\%} (14/17) in the 100 mg b.i.d. group. Eradication of major causative organisms was 91.7{\%} (22/24) in S. pneumoniae and 100{\%} (24/24) in Haemophilus influenzae. Steady state Cmax and AUC0-24h after repeated oral administration of STFX to patients with RTI were 0.57 ± 0.21 μg/mL and 9.38 ± 424 μg · h/mL in the 50 mg b.i.d, group, and 1.17 ± 0.45 μg/mL and 17.16 ± 6.52 χ • h/mL in the 100 mg b.i.d. group. If Cmax/MIC was 5 or below, or AUC0-24h/MIC was 100 or below, eradication were 33.3{\%} (3/9) or 40.0{\%} (4/10). In contrast, if Cmax/MIC was over 5, it was 96.3{\%} (79/82). If AUC0-24h/MIC was over 100, it was 96.3{\%} (78/81). MIC90 of STFX against the causative organisms in this study was 0.1 μg/mL. Results suggest that 50 mg b.i.d of STFX can achieve Cmax/MIC5 and AUC0-24h/ MIC 100 against 90{\%} of the causative organisms in RTI. Adverse drug reactions(ADR) occurred in 43.5{\%} (50/115 patients) in the 50 mg b.i.d, group and 42.4{\%} (14/33 patients) in the 100 mg b.i.d, group. The major ADR was diarrhoea (20/148, 13.5{\%}). Cmax and AUC0-24h of patients in whom diarrhoea or soft stool occurred tended to be higher than in patients free of these symptoms. No severe ADRs were observed in either groups. Results suggest that a dose of 50 mg b.i.d, of STFX is optimal in the treatment of RTI.",
keywords = "Fluoroquinolone, PK/PD, Respiratory tract infection, Sitafloxacin",
author = "Atsushi Saito and Yusuke Tanigawara and Akira Watanabe and Nobuki Aoki and Yoshihito Niki and Shigeru Kohno and Mitsuo Kaku and Seiji Hori and Kyoichi Totsuka",
year = "2008",
month = "4",
language = "English",
volume = "56",
pages = "63--80",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Open study of sitafloxacin in patients with respiratory tract infections - PK/PD study

AU - Saito, Atsushi

AU - Tanigawara, Yusuke

AU - Watanabe, Akira

AU - Aoki, Nobuki

AU - Niki, Yoshihito

AU - Kohno, Shigeru

AU - Kaku, Mitsuo

AU - Hori, Seiji

AU - Totsuka, Kyoichi

PY - 2008/4

Y1 - 2008/4

N2 - Sitafloxacin(STFX), a fluoroquinolone antimicrobial agent, has a broad spectrum of activity and a potent antimicrobial activity against Streptococcus pneumoniae which is a major pathogen in respiratory tract infections(RTI). This clinical study was conducted to confirm the clinical recommended dose of STFX as 50 mg b. i.d. for RTI from PK/PD. Clinical efficacy was 92.3% (96/104) in the 50 mg b.i.d, group and 93.1% (27/29) in the 100 mg b.i.d, group. Bacteriological efficacy was 89.1% (57/64) in the 50 mg b.i.d, group and 82.4% (14/17) in the 100 mg b.i.d. group. Eradication of major causative organisms was 91.7% (22/24) in S. pneumoniae and 100% (24/24) in Haemophilus influenzae. Steady state Cmax and AUC0-24h after repeated oral administration of STFX to patients with RTI were 0.57 ± 0.21 μg/mL and 9.38 ± 424 μg · h/mL in the 50 mg b.i.d, group, and 1.17 ± 0.45 μg/mL and 17.16 ± 6.52 χ • h/mL in the 100 mg b.i.d. group. If Cmax/MIC was 5 or below, or AUC0-24h/MIC was 100 or below, eradication were 33.3% (3/9) or 40.0% (4/10). In contrast, if Cmax/MIC was over 5, it was 96.3% (79/82). If AUC0-24h/MIC was over 100, it was 96.3% (78/81). MIC90 of STFX against the causative organisms in this study was 0.1 μg/mL. Results suggest that 50 mg b.i.d of STFX can achieve Cmax/MIC5 and AUC0-24h/ MIC 100 against 90% of the causative organisms in RTI. Adverse drug reactions(ADR) occurred in 43.5% (50/115 patients) in the 50 mg b.i.d, group and 42.4% (14/33 patients) in the 100 mg b.i.d, group. The major ADR was diarrhoea (20/148, 13.5%). Cmax and AUC0-24h of patients in whom diarrhoea or soft stool occurred tended to be higher than in patients free of these symptoms. No severe ADRs were observed in either groups. Results suggest that a dose of 50 mg b.i.d, of STFX is optimal in the treatment of RTI.

AB - Sitafloxacin(STFX), a fluoroquinolone antimicrobial agent, has a broad spectrum of activity and a potent antimicrobial activity against Streptococcus pneumoniae which is a major pathogen in respiratory tract infections(RTI). This clinical study was conducted to confirm the clinical recommended dose of STFX as 50 mg b. i.d. for RTI from PK/PD. Clinical efficacy was 92.3% (96/104) in the 50 mg b.i.d, group and 93.1% (27/29) in the 100 mg b.i.d, group. Bacteriological efficacy was 89.1% (57/64) in the 50 mg b.i.d, group and 82.4% (14/17) in the 100 mg b.i.d. group. Eradication of major causative organisms was 91.7% (22/24) in S. pneumoniae and 100% (24/24) in Haemophilus influenzae. Steady state Cmax and AUC0-24h after repeated oral administration of STFX to patients with RTI were 0.57 ± 0.21 μg/mL and 9.38 ± 424 μg · h/mL in the 50 mg b.i.d, group, and 1.17 ± 0.45 μg/mL and 17.16 ± 6.52 χ • h/mL in the 100 mg b.i.d. group. If Cmax/MIC was 5 or below, or AUC0-24h/MIC was 100 or below, eradication were 33.3% (3/9) or 40.0% (4/10). In contrast, if Cmax/MIC was over 5, it was 96.3% (79/82). If AUC0-24h/MIC was over 100, it was 96.3% (78/81). MIC90 of STFX against the causative organisms in this study was 0.1 μg/mL. Results suggest that 50 mg b.i.d of STFX can achieve Cmax/MIC5 and AUC0-24h/ MIC 100 against 90% of the causative organisms in RTI. Adverse drug reactions(ADR) occurred in 43.5% (50/115 patients) in the 50 mg b.i.d, group and 42.4% (14/33 patients) in the 100 mg b.i.d, group. The major ADR was diarrhoea (20/148, 13.5%). Cmax and AUC0-24h of patients in whom diarrhoea or soft stool occurred tended to be higher than in patients free of these symptoms. No severe ADRs were observed in either groups. Results suggest that a dose of 50 mg b.i.d, of STFX is optimal in the treatment of RTI.

KW - Fluoroquinolone

KW - PK/PD

KW - Respiratory tract infection

KW - Sitafloxacin

UR - http://www.scopus.com/inward/record.url?scp=43449091278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43449091278&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:43449091278

VL - 56

SP - 63

EP - 80

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - SUPPL. 1

ER -